Ionis Pharmaceuticals, Inc. (IONS)
Nasdaq · Healthcare · Biotechnology
$43.50−0.09%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $7.2B
- 52-week range
- $42.63 – $86.74
- 52-week change
- −36.84%
- EPS (trailing)
- −$3.48
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $944M (+33.83%)
- Net income
- −$381M
- Operating margin
- −40.4%
- Diluted EPS
- −$2.38
- Free cash flow
- −$320M
From the company’s annual report on SEC EDGAR.
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease.
Headquarters: Carlsbad, United States · 1,480 employees · ionis.com